Tech glitches overshadow FDA oncology adcomm as a solid majority of advisers vote to keep Roche's Tecentriq in mTNBC
Kicking off three days of reexamining anti-PD(L)-1 accelerated approvals, the FDA’s Oncologic Drugs Advisory Committee started slowly on Tuesday. After a more than hour-long technical delay, members voted 7-2 to keep alive the accelerated approval for Genentech’s Tecentriq (atezolizumab) plus Abraxane (nab-paclitaxel) in metastatic triple negative breast cancer (mTNBC) while additional confirmatory trials are ongoing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.